# Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

> **NCT00496197** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 282 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** Eraxis (anidulafungin)
- **DRUG:** Diflucan (fluconazole)
- **DRUG:** Vfend (voriconazole)

## Key facts

- **NCT ID:** NCT00496197
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2011-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496197, "Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00496197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*